Imfinzi and Tumor marker increased - a phase IV clinical study of FDA data

Summary:

Tumor marker increased is reported as a side effect among people who take Imfinzi (durvalumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Etoposide, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Tumor marker increased when taking Imfinzi. It is created by eHealthMe based on reports of 8,352 people who have side effects when taking Imfinzi from the FDA, and is updated regularly.

What is Imfinzi?

Imfinzi has active ingredients of durvalumab. eHealthMe is studying from 8,353 Imfinzi users. Check the latest studies of Imfinzi.

What is Tumor marker increased?

Tumor marker increased is found to be associated with 351 drugs and 388 conditions by eHealthMe. Check the latest studies of Tumor marker increased.

On Jul, 12, 2026

8,352 people reported to have side effects when taking Imfinzi.
Among them, 17 people (0.2%) have Tumor marker increased.

Could Imfinzi cause Tumor marker increased?

Among these 17 people:

How long have people been on Imfinzi when they have Tumor marker increased? *

What is the gender of people who have Tumor marker increased when taking Imfinzi? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Tumor marker increased when taking Imfinzi? *

What are other drugs people take besides Imfinzi? *

Etoposide: 4 people, 23.53%
Imjudo: 3 people, 17.65%
Cisplatin: 3 people, 17.65%
Hydromorphone Hydrochloride: 2 people, 11.76%
Fexofenadine Hydrochloride: 2 people, 11.76%
Carboplatin: 2 people, 11.76%
Magnesium Oxide: 1 person, 5.88%
Jardiance: 1 person, 5.88%
Gemcitabine Hydrochloride: 1 person, 5.88%
Amlodipine: 1 person, 5.88%

What are other side effects people have besides Tumor marker increased? *

Fever: 5 people, 29.41%
Hepatic Function Abnormal: 3 people, 17.65%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 17.65%
Hepatic Enzyme Increased: 2 people, 11.76%
High Blood Pressure: 2 people, 11.76%
Hyperthyroidism (over activity of the thyroid gland): 2 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 11.76%
Inflammation: 2 people, 11.76%
Liver Disorder (liver diseases): 2 people, 11.76%
Thyroiditis (inflammation of thyroid gland): 2 people, 11.76%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 5 people, 29.41%
Lung Cancer - Small Cell (lung cancer): 4 people, 23.53%
Hepatocellular Carcinoma (liver cancer): 3 people, 17.65%
Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 11.76%
Chest Pain: 2 people, 11.76%
Asthma: 2 people, 11.76%
Gastrointestinal Carcinoma (cancer of stomach or intestine): 1 person, 5.88%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Imfinzi and have Tumor marker increased?

- Check whether Tumor marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imfinzi:

Imfinzi (8,353 reports)

Browse all side effects of Imfinzi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor marker increased:

Tumor marker increased (351 drugs)

Browse all the conditions that are associated with Tumor marker increased:

Tumor marker increased (388 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on durvalumab (the active ingredients of Imfinzi) and Imfinzi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.